These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 12800807)

  • 41. Comparison of the Bayesian approach and a limited sampling model for the estimation of AUC and Cmax: a computer simulation analysis.
    Mahmood I; Miller R
    Int J Clin Pharmacol Ther; 1999 Sep; 37(9):439-45. PubMed ID: 10507242
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bayesian estimation of p-aminohippurate clearance by a limited sampling strategy.
    Kinowski JM; Rodier M; Bressolle F; Fabre D; Augey V; Richard JL; Galtier M; Gomen R
    J Pharm Sci; 1995 Mar; 84(3):307-11. PubMed ID: 7616369
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An evaluation of population D-optimal designs via pharmacokinetic simulations.
    Hooker AC; Foracchia M; Dodds MG; Vicini P
    Ann Biomed Eng; 2003 Jan; 31(1):98-111. PubMed ID: 12572660
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessment of type I error rates for the statistical sub-model in NONMEM.
    Wählby U; Bouw MR; Jonsson EN; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2002 Jun; 29(3):251-69. PubMed ID: 12449498
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparing models for perfluorooctanoic acid pharmacokinetics using Bayesian analysis.
    Wambaugh JF; Barton HA; Setzer RW
    J Pharmacokinet Pharmacodyn; 2008 Dec; 35(6):683-712. PubMed ID: 19130186
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Bayesian meta-analysis on published sample mean and variance pharmacokinetic data with application to drug-drug interaction prediction.
    Yu M; Kim S; Wang Z; Hall S; Li L
    J Biopharm Stat; 2008; 18(6):1063-83. PubMed ID: 18991108
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients.
    Peng B; Boddy AV; Cole M; Pearson AD; Chatelut E; Rubie H; Newell DR
    Eur J Cancer; 1995 Oct; 31A(11):1804-10. PubMed ID: 8541105
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects.
    Plock N; Facius A; Hartmann L; Baumann S; Nave R
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):495-508. PubMed ID: 23611571
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies.
    Ette EI; Howie CA; Kelman AW; Whiting B
    Pharm Res; 1995 May; 12(5):729-37. PubMed ID: 7479560
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design and power of a population pharmacokinetic study.
    Lee PI
    Pharm Res; 2001 Jan; 18(1):75-82. PubMed ID: 11336356
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design.
    Leroux S; Turner MA; Guellec CB; Hill H; van den Anker JN; Kearns GL; Jacqz-Aigrain E; Zhao W;
    Clin Pharmacokinet; 2015 Dec; 54(12):1273-85. PubMed ID: 26063050
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison of two sparse sampling population pharmacokinetic approaches for the estimation of pharmacokinetic parameters in children.
    Mahmood I; Tammara V
    Int J Clin Pharmacol Ther; 2004 Apr; 42(4):240-5. PubMed ID: 15124982
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model.
    Duval V; Karlsson MO
    Pharm Res; 2002 Dec; 19(12):1835-40. PubMed ID: 12523662
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer.
    Climente-Martí M; Merino-Sanjuán M; Almenar-Cubells D; Jiménez-Torres NV
    J Pharm Sci; 2003 Jun; 92(6):1155-65. PubMed ID: 12761805
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bayesian estimation of doxorubicin pharmacokinetic parameters.
    Bressolle F; Ray P; Jacquet JM; Brès J; Galtier M; Donadio D; Jourdan J; Rossi JF
    Cancer Chemother Pharmacol; 1991; 29(1):53-60. PubMed ID: 1742849
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The impact of compliance in pharmacokinetic studies.
    Vrijens B; Goetghebeur E
    Stat Methods Med Res; 1999 Sep; 8(3):247-62. PubMed ID: 10636337
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.
    Staatz CE; Tett SE
    Eur J Clin Pharmacol; 2002 Dec; 58(9):597-605. PubMed ID: 12483452
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma.
    Rousseau A; Sabot C; Delepine N; Delepine G; Debord J; Lachâtre G; Marquet P
    Clin Pharmacokinet; 2002; 41(13):1095-104. PubMed ID: 12403645
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Methods to detect non-compliance and reduce its impact on population PK parameter estimates.
    Gibiansky L; Gibiansky E; Cosson V; Frey N; Stark FS
    J Pharmacokinet Pharmacodyn; 2014 Jun; 41(3):279-89. PubMed ID: 24952228
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.
    Dumont C; Mentré F; Gaynor C; Brendel K; Gesson C; Chenel M
    Clin Pharmacokinet; 2013 Jan; 52(1):43-57. PubMed ID: 23212609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.